The raised guidance and strong cash generation support continued organic growth. Watch for the January 2027 detailed guidance and any M&A announcements that could further accelerate growth.
Drugs in focus
KMDA drug pipeline →CYTOGAM
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already FDA-approved and commercially marketed
- Next catalyst
- None dated
What to watchCYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 9 $7.71entry
- T+1 · 7d ago +5.06%α +5.43% · $8.10
- T+5 · 17h ago +5.19%α +6.88% · $8.11
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kamada reported Q3 2026 revenue of $52.0M (+11% YoY) and EPS of $0.14, beating the $0.13 consensus. The company raised its full-year 2026 guidance to $205M-$208M revenue and $52M-$54M adjusted EBITDA, citing strong demand for KEDRAB and other plasma-derived products.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $52.0M, up 11% YoY from $47.0M
- Q3 2026 GAAP diluted EPS $0.14, up 56% from $0.09 YoY
- Q3 2026 adjusted EBITDA $15.2M, up 30% YoY, margin 29%
- Q3 2026 net income $8.0M, up 51% YoY
- Full-year 2026 guidance raised: revenue $205M-$208M (midpoint +14% YoY), adjusted EBITDA $52M-$54M (midpoint +26% YoY)
- Cash from operations $19.9M in Q3, up 91% YoY; cash balance $75.3M
- Declared $0.14/share dividend (~$8.0M); total 2026 dividends $0.56/share (~$32.2M)
- EPS of $0.14 beat consensus of $0.13 (surprise +7.7%)
- Revenue of $52.0M vs consensus $158.6M (note: consensus appears to be for nine-month period, not Q3 alone)
Financial Impact
Q3 revenue beat consensus by ~$1.5M (based on $52.0M vs $50.5M implied quarterly run-rate from $158.6M nine-month consensus); guidance raised by $4M at midpoint for revenue and $1.5M for adjusted EBITDA
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Proprietary products | $44.2M | +11.8% |
| Distribution | $7.8M | +4.8% |
Risk Factors
- Geopolitical risks from Middle East conflicts and potential tariffs
- Dependence on KEDRAB and other plasma-derived products for growth
- Execution risk on biosimilar portfolio expansion and plasma collection ramp-up
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398271 |
Track record
25 reports on KMDA
7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 No price data
- Nov 9, 20267d ago Press Release Bullish 6/10 Viewing Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
- Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
- Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
- Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
- Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers